Cord blood stem cells take on deadly transplant complication

NCT ID NCT03847844

Completed Disease control Sponsor: Cytopeutics Sdn. Bhd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether stem cells from donated umbilical cords (Cyto-MSC) could help treat acute graft-versus-host disease (GVHD), a serious complication after bone marrow transplants. Twenty-six patients with moderate to severe GVHD received the stem cells plus standard steroids. The goal was to see if this combination could improve response rates and survival. The trial was completed, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord mesenchymal stem cells (Cyto-MSC)
What this could lead to: If it works, this could provide a new front-line treatment option for acute graft-versus-host disease, potentially improving survival and reducing complications.
What could go wrong: This is an early-phase trial with only 26 participants, so results may not apply to all patients. Stem cell therapies can carry risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

Hospital Ampang

Ampang, Selangor, 68000, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.